Wound care company Nuo Therapeutics (OTC:NUOT) said yesterday that a federal court in Delaware approved a bankruptcy plan that would either see it continue as an independent company or become 95% owned by lender Deerfield Management. Gaithersburg, Md.-based Nuo filed for Chapter 11 bankruptcy protection in January, 2 years after raising $35 million from Deerfield. Formerly known as Cytomedix, […]
Nuo Therapeutics files for bankruptcy
Wound care company Nuo Therapeutics (OTC:NUOT) said yesterday that it’s declaring Chapter 11 bankruptcy a little more than 2 years after raising $35 million. Formerly known as Cytomedix, Nuo Therapeutics makes the Aurix hematogel, which is designed to stimulate the body’s native mechanisms to heal wounds. In April 2014, the company landed a $35 million investment from Deerfield […]
DOD hands out $99.6 million in contracts to Hologic, GE, PositiveID | Medtech funding stories for the week of Apr. 7, 2014
Stryker hits a new lifetime high in shares | Medtech Wall Street news for the week of Apr. 7, 2014
Deerfield raises $1.6B healthcare fund
Deerfield Management Co. said it raised a fund aimed at healthcare investments that’s worth $1.6 billion.
Deerfield Private Design Fund III is "designed to provide flexible private financing to healthcare companies," according to a press release.
Stealthy Auris Surgical Robotics raises more than $34 million in an equity round | Medtech funding stories for the week of Mar. 31, 2014
Cytomedix lands $35M for wound care products
Cytomedix raises $3M for regenerative therapies
Cytomedix touts reimbursement win
Cytomedix (OTC:CMXI) touted a reimbursement win from the Centers for Medicare & Medicaid Services for plasma systems including its AutoloGel product.
The coverage decision includes Cytomedix’s platelet-rich plasma system for patients with chronic ulcers and wounds, under the Coverage with Evidence Development program, a CMS guidance policy that gathers data and public comments to include in coverage decisions.
